Overview

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas

Status:
RECRUITING

Trial end date:
2033-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Phase:

PHASE1

Details

Lead Sponsor:

University of Utah

Collaborator:

Ipsen

Treatments:

obinutuzumab
Rituximab
tazemetostat
zanubrutinib